Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling

Diabetes

Volumn 62, Issue 7, 2013, Pages 2539-2544

  Varewijck, Aimee J ^a   Yki Järvinen, Hannele ^b,c   Schmidt, Ronald ^d   Tennagels, Norbert ^e   Janssen, Joseph A M J L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HELSINKI   (Finland)

^c MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^d Disposition   (Germany)

^e Diabetes Division   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN RECEPTOR; INSULIN RECEPTOR A; INSULIN RECEPTOR B; ISOPHANE INSULIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLARGINE; LONG ACTING INSULIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; BLOOD; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; LIQUID CHROMATOGRAPHY; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84883699116     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1773     Document Type: Article

References (23)

1. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-1765
2. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
3. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-1744
4. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a populationbased follow-up study in Sweden. Diabetologia 2009;52:1745-1754
5. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005
6. Sommerfeld MR, Müller G, Tschank G, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 2010;5:e9540
7. Varewijck AJ, Janssen JA, Vähätalo M, Hofland LJ, Lamberts SW, Yki- Järvinen H. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia 2012;55:1186-1194
8. Lucidi P, Porcellati F, Rossetti P, et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care 2012;35:2647-2649
9. Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003;19:34-40
10. Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012;35:2626-2630
11. Sciacca L, Le Moli R, Vigneri R. Insulin analogs and cancer. Front Endocrinol (Lausanne) 2012;3:21
12. Ish-Shalom D, Christoffersen CT, Vorwerk P, et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997;40(Suppl. 2):S25-S31
13. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278-3288
14. Papa V, Pezzino V, Costantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990;86:1503-1510
15. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623
16. Benecke H, Flier JS, Moller DE. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. J Clin Invest 1992;89:2066-2070
17. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 1990;9:2409-2413
18. Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 1989;86: 114-118
19. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451
20. Chen JW, Ledet T, Orskov H, et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 2003;284:E1149-E1155
21. Varewijck AJ, Brugts MP, Frystyk J, et al. Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling. Mol Cell Endocrinol 2013; 365:17-24
22. Pierre-Eugene C, Pagesy P, Nguyen TT, et al. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS ONE 2012;7:e41992
23. Nagel JM, Staffa J, Renner-Müller I, et al. Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 2010; 1:320-330